Pfizer agreed to pay $325 million to wrap up claims that its Parke-Davis unit touted the epilepsy drug Neurontin for uses not approved by the FDA, costing healthcare payers millions in unnecessary spending. Read the full story
Pfizer agreed to pay $325 million to wrap up claims that its Parke-Davis unit touted the epilepsy drug Neurontin for uses not approved by the FDA, costing healthcare payers millions in unnecessary spending. Read the full story
GSK agreed to pay $105 million to settle charges in California, New York, Texas and more than 40 other states that it illegally promoted its asthma drug Advair and antidepressants Wellbutrin and Paxil. Read the full story
Boehringer Ingelheim has agreed to pay $650 million to wrap up thousands of lawsuits claiming Pradaxa, an anticoagulant, caused serious--even fatal--bleeding in some patients. Read the full story
Medtronic has reached a global patent settlement agreement with Edwards Lifesciences. Read the full story
Actavis has entered into an agreement with Valeant Pharmaceuticals to settle all outstanding patent litigation related to Actavis' generic version of Acanya (clindamycin phosphate and benzoyl peroxide) Gel, 1.2%/2.5%. Read the full story
Mylan Pharmaceuticals and pharma alliances, Banner Pharmacaps have entered into a settlement and license agreement with Eisai and Valeant Pharmaceuticals. Read the full story
Johnson & Johnson has settled a pharma deal of 8,000 lawsuits.over defective DePuy Hip Replacement ASR devices.
Teva, a big pharma in Israel, pays the Israel government $565 million taxes due to trapped profits. Read the full story
Johnson & Johnson agrees to pay a settlement of $2.2 billion for a dispute of over 8 years.
Anacor Pharmaceuticals has entered into a settlement agreement with big pharma, Valeant Pharmaceuticals.